| sorafenib / Generic mfg. |
NCT00101413: BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) |
|
|
| Completed | 2 | 52 | US, Europe | Sorafenib (Nexavar, BAY43-9006) | Bayer, Amgen | Cancer, Carcinoma, Non-Small Cell Lung | 06/05 | 04/08 | | |
NCT00095693: Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer |
|
|
| Terminated | 2 | 25 | US | sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, laboratory biomarker analysis, pharmacological study, pharmacological studies, fludeoxyglucose F 18, 18FDG, FDG, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, dynamic contrast-enhanced magnetic resonance imaging, DCE-MRI | National Cancer Institute (NCI) | Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer | 08/05 | 12/11 | | |
NCT00117637 / 2005-000544-86: BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma |
|
|
| Completed | 2 | 189 | US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006), Interferon | Bayer | Carcinoma, Renal Cell | 09/06 | 03/09 | | |
NCT00096395: Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer |
|
|
| Completed | 2 | 33 | Canada | gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, laboratory biomarker analysis | National Cancer Institute (NCI) | Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer | 02/07 | | | |
NCT00107432: Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. |
|
|
| Completed | 2 | 44 | US | sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, laboratory biomarker analysis | National Cancer Institute (NCI) | Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma | 06/07 | | | |
NCT00522301: Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission |
|
|
| Terminated | 2 | 6 | US | sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Bayer | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | 03/08 | 03/08 | | |
NCT00253370: Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 44 | US | BAY 43-9006, Sorafenib (NSC724772), BAY 54-9085 (tosylate salt), docetaxel, Taxotere, RP 56976, NSC #628503, cisplatin, Cis-diaminedichloroplatinum, Cis-diaminedichloroplatinum (II), diaminedichloroplatinum, cis-platinum, platinum, Platinol, Platinol-AQ, DDP, CDDP, DACP, NSC 119875. | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer | 05/08 | 09/10 | | |
NCT00544817: Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme |
|
|
| Completed | 2 | 47 | US | Radiation Therapy, Temozolomide, Temodar, Sorafenib, Nexavar | SCRI Development Innovations, LLC, Bayer | Glioblastoma Multiforme | 06/08 | 08/10 | | |
| Completed | 2 | 142 | Europe | Sorafenib (BAY-43-9006) | Istituto Clinico Humanitas | Carcinoma, Hepatocellular | 06/08 | | | |
NCT00445042: Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer |
|
|
| Completed | 2 | 71 | US | Sorafenib, Nexavar | The Methodist Hospital Research Institute, Bayer, Amgen | Carcinoma, Renal Cell | 09/08 | 10/08 | | |
|
| Terminated | 2 | 134 | Europe | Sorafenib, Nexavar | Johannes Gutenberg University Mainz | Carcinoma, Non-Small-Cell Lung | 09/08 | 09/08 | | |
NCT00597493: Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM |
|
|
| Completed | 2 | 32 | US | Sorafenib and Temozolomide, Temodar, Nexavar | Duke University, Bayer, Schering-Plough | Recurrent Glioblastoma Multiforme | 02/09 | 12/10 | | |
NCT00854620: Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer |
|
|
| Completed | 2 | 9 | US | Sorafenib, Nexavar, Sorafenib tosylate | Stanford University | Carcinoma, Renal Cell, Kidney Disease, Kidney Cancer | 07/09 | 01/11 | | |
NCT00866320: Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab |
|
|
| Completed | 2 | 49 | US | sorafenib tosylate | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Kidney Cancer | 12/09 | 12/09 | | |
|
| Completed | 2 | 75 | RoW | Sorafenib | Egyptian Foundation For Cancer Research | Metastatic Renal Cell Carcinoma | 12/09 | 03/10 | | |
NCT00466752: Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer |
|
|
| Completed | 2 | 5 | US | sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, microarray analysis, gene expression profiling, immunohistochemistry staining method, immunohistochemistry, gene expression analysis, needle biopsy, aspiration biopsy, puncture biopsy, therapeutic conventional surgery, laboratory biomarker analysis, western blotting, Blotting, Western, Western Blot, RNA analysis | University of Washington, National Cancer Institute (NCI) | Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer | 04/10 | 07/11 | | |
| Completed | 2 | 152 | US, Europe | AMG 386, Sorafenib, AMG 386 placebo IV | Amgen | Advanced Renal Cell Carcinoma | 04/10 | 06/14 | | |
|
NCT00112671: Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract |
|
|
| Completed | 2 | 17 | Canada | sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, laboratory biomarker analysis | National Cancer Institute (NCI) | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder | 05/10 | 05/10 | | |
NCT00131911: Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
|
|
| Completed | 2 | 93 | US | sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN | National Cancer Institute (NCI) | Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Neuroendocrine Tumor, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma, WDHA Syndrome | 10/10 | 04/13 | | |
NCT00621686: Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme |
|
|
| Completed | 2 | 54 | US | bevacizumab, sorafenib tosylate | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | 10/10 | 02/14 | | |
|
|
NCT00919009: Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC) |
|
|
| Completed | 2 | 50 | RoW | TACE (Transcatheter Arterial Chemoembolization ) | National Cancer Center, Korea | Carcinoma, Hepatocellular | 05/11 | 12/11 | | |
|
|
|
| Completed | 2 | 70 | RoW | BAY86-9766 MEK Inhibitor + Sorafenib | Bayer | Carcinoma, Hepatocellular | 08/11 | 08/13 | | |
|
|
NCT00875615: Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 11 | US | Carboplatin, Cisplatin, Sorafenib | University of Miami | Liver Cancer | 06/12 | 06/12 | | |
| Completed | 2 | 57 | Europe | 4SC-201, Sorafenib | 4SC AG | Hepatocellular Carcinoma | 06/12 | 09/13 | | |
|
|
|
NCT00480389: Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal |
|
|
| Completed | 2 | 19 | Canada | Sorafenib, Nexavar | University Health Network, Toronto, Bayer | Renal Cell Carcinoma, Metastatic Disease | 10/12 | 03/13 | | |
| Completed | 2 | 54 | Europe | sorafenib tosylate, laboratory biomarker analysis | Cancer Trials Ireland | Esophageal Cancer, Gastric Cancer | 11/12 | | | |
|
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
NCT01100242: Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma |
|
|
| Terminated | 2 | 17 | US | Velcade and Sorafenib, velcade, bortezomib, sorafenib | New Mexico Cancer Care Alliance | Metastatic Renal Cell Carcinoma | 01/14 | 02/15 | | |
|
NCT01375569: TRC105 for Liver Cancer That Has Not Responded to Sorafenib |
|
|
| Completed | 2 | 11 | US | TRC105 | National Cancer Institute (NCI) | Hepatocellular Carcinoma, Hepatocellular Cancer, Carcinoma, Hepatocellular | 02/14 | 12/15 | | |
NCT01232296: A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment |
|
|
| Completed | 2 | 162 | Japan, RoW | dovitinib, TKI258, sorafenib | Novartis Pharmaceuticals | Hepatocellular Carcinoma | 04/14 | 04/14 | | |
|
NCT01502410: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer |
|
|
| Completed | 2 | 20 | US, Canada, RoW | sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, pharmacological study, pharmacological studies, laboratory biomarker analysis | National Cancer Institute (NCI) | Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Thyroid Cancer, Recurrent Wilms Tumor and Other Childhood Kidney Tumors | 06/14 | 06/14 | | |
NCT00808145: Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Withdrawn | 2 | 0 | US | Gemcitabine / Cisplatin / Sorafenib, nexavar - sorafenib, gemzar - gemcitabine, cisplatin | Lahey Clinic | Hepatocellular Carcinoma | 10/14 | 10/14 | | |
NCT01189370: Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer |
|
|
| Completed | 2 | 25 | US | sorafenib, BAY 43-9006, Nexavar® | University of Kansas Medical Center, Bayer | Renal Cell Cancer | 04/15 | 04/15 | | |
NCT01480817: Sorafenib VS TACE in HCC Patients With Portal Vein Invasion |
|
|
| Terminated | 2 | 2 | RoW | Sorafenib, Nexavar, TACE for HCC with portal vein invasion, TACE | Seoul National University Hospital | Hepatocellular Carcinoma | 12/15 | 12/15 | | |
NCT01616186: Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) |
|
|
| Withdrawn | 2 | 0 | US | Everolimus and sorafenib, Sunitinib monotherapy | Andrea Harzstark, Novartis | Locally Metastatic Malignant Neoplasm | 12/15 | 04/16 | | |
| Completed | 2 | 160 | Europe | sorafenib, Pravastatin, Sorafenib + Pravastatin, patients receiving best supportive care | University Hospital, Bordeaux, Federation Francophone de Cancerologie Digestive, UNICANCER | Hepatocellular Carcinoma, CHILD B | 04/17 | 04/17 | | |
NCT01897610: Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC |
|
|
| Completed | 2 | 40 | RoW | Immuncell-LC, Activated T lymphocyte | GC Cell Corporation | Advanced Hepatocellular Carcinoma | 07/17 | 07/17 | | |
NCT01498952: MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. |
|
|
| Completed | 1b/2 | 6 | US | MEDI-573 (1 of 3 doses), Sorafenib | MedImmune LLC | Unresectable or Metastatic Hepatocellular Carcinoma (HCC) | 04/13 | 04/13 | | |
NCT00389285: Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma |
|
|
| Completed | 1/2 | 52 | US | rIL-21 only, rIL-21 + sorafenib | ZymoGenetics | Carcinoma, Renal Cell | 05/09 | 05/09 | | |
NCT00448149: Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer |
|
|
| Completed | 1/2 | 55 | US | RAD001, Everolimus, Sorafenib, Nexavar®, BAY-4900 | The Methodist Hospital Research Institute, Novartis Pharmaceuticals | Carcinoma, Renal Cell | 06/09 | 06/09 | | |
|
|
NCT00712790: Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) |
|
|
| Completed | 1/2 | 35 | RoW | Sorafenib, BAY 43-9006, SIR-Spheres, Yttrium-90 Microspheres | Singapore Clinical Research Institute, National Medical Research Council (NMRC), Singapore, Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, Sirtex Medical | Hepatocellular Carcinoma | 06/09 | 04/14 | | |
|
|
NCT00971126: Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) |
|
|
| Terminated | 1/2 | 3 | RoW | sorafenib (Nexavar®), thalidomide (Thado®), Nexavar®), Thado® | National Health Research Institutes, Taiwan, National Cheng-Kung University Hospital, Chang Gung Memorial Hospital | Hepatocellular Carcinoma | 01/10 | 03/10 | | |
| Completed | 1/2 | 22 | Europe | Sorafenib, Nexavar (brand name), Transarterial chemoembolisation (TACE) | Medical University of Vienna | Hepatocellular Carcinoma | 10/10 | 11/10 | | |
|
NCT00882869: XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Completed | 1/2 | 75 | RoW | AEG35156 antisense IV infusion, Sorafenib, nexavar | Aegera Therapeutics, Chinese University of Hong Kong | Advanced Hepatocellular Carcinoma | 03/11 | 05/11 | | |
|
|
NCT00734526: Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma |
|
|
| Terminated | 1/2 | 18 | US | Temozolomide, Radiation, Radiotherapy, XRT, Sorafenib, BAY43-9006 | M.D. Anderson Cancer Center, Bayer | Glioblastoma, Gliosarcoma | 12/12 | 12/12 | | |
NCT01335074: Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Withdrawn | 1/2 | 0 | Europe | Temsirolimus + Sorafenib | Philipps University Marburg Medical Center | Hepatocellular Carcinoma | 12/13 | | | |
NCT01754987: A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective |
|
|
| Completed | 1/2 | 5 | US | Ascorbic Acid + Sorafenib, Vitamin C, Ascorbate, Sorafenib, Nexavar | Thomas Jefferson University | Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer | 01/16 | 01/16 | | |
